A Phase II Study of Iodine-131 Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients with Advanced Stage Follicular Non-Hodgkin’s Lymphoma May 5, 2022 By Jesse Bufkin
A Phase I Trial of Bendamustine/Treanda, Rituximab, Etoposide, and Carboplatin for Patients with Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC) May 5, 2022 By Jesse Bufkin
A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas May 5, 2022 By Jesse Bufkin
Impact of Short-term Hyperglycemia on Beta-cell Function and Insulin Sensitivity in Subjects with Impaired Glucose Tolerance May 5, 2022 By Jesse Bufkin
An Open-Label Study of Certolizumab Pegol (Cimzia), a Pegylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor in Subjects with Moderate to Severe Crohn’s Disease May 5, 2022 By Jesse Bufkin
An open-label, multicenter, randomized Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s Lymphoma (NHL) May 5, 2022 By Jesse Bufkin
ECOG E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas May 5, 2022 By Jesse Bufkin
